Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Annual General Meeting

Shukra Pharmaceuticals Ltd issued a corrigendum to its Postal Ballot notice regarding the proposed alteration of its Main Object Clause and name change.

Shukra Pharmaceuticals Annual Report

Shukra Pharmaceuticals Ltd has filed its 32nd Annual Report for the financial year 2025-26 as mandated by SEBI (LODR) regulations. The document covers the company's annual activities.

Shukra Pharmaceuticals Annual General Meeting

Shukra Pharmaceuticals has scheduled its 33rd Annual General Meeting on September 28, 2026, to be held via Video Conferencing.

Shukra Pharmaceuticals Dividend

Shukra Pharmaceuticals Ltd has fixed September 21, 2026, as the record date for a final dividend of ₹0.01 per share. Payment is subject to shareholder approval.

Shukra Pharmaceuticals Capital Structure Change

Shukra Pharmaceuticals allotted 11,73,000 equity shares following the conversion of warrants, generating Rs.3.13 Crore in exercise proceeds. This allotment increases the company's paid-up equity capital.

Value

₹3.13 Cr

Shukra Pharmaceuticals Q1 FY27 Results: Net Profit ₹13 Cr, Up 1200.0% YoY

Shukra Pharmaceuticals Ltd reported revenue from operations of ₹23.5 Cr (+335.2% YoY) and net profit of ₹13 Cr (+1200.0% YoY) for Q1 FY27.

Key figure

Net profit ₹13 Cr · +1200.0% YoY

Shukra Pharmaceuticals Q4 FY26 Results: Net Loss of ₹1.7 Cr

Shukra Pharmaceuticals Ltd reported revenue from operations of ₹6.3 Cr (-52.6% YoY) and a net loss of ₹1.7 Cr for Q4 FY26.

Key figure

Net loss ₹1.7 Cr